The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Compare Between 2026 And 2030?
The market size for ornithine transcarbamylase deficiency (otc deficiency) has seen substantial growth over recent years. It is forecast to rise from $0.89 billion in 2025 to $0.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the preceding period can be ascribed to several factors, including limited therapeutic options and a high disease burden, increasing awareness of otc deficiency among neonates, the early adoption of liver transplantation and dietary management techniques, a rise in research pertaining to rare genetic disorders, and the growing incidence of hyperammonemia-related complications.
The ornithine transcarbamylase deficiency (otc deficiency) market size is anticipated to demonstrate strong growth in the coming years, with projections indicating it will reach $1.23 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period can be attributed to an expanding pipeline of gene and mRNA-based therapies, increasing availability of enzyme replacement and protein engineering solutions, a growing adoption of precision medicine approaches, rising investments in rare disease research, and the expansion of diagnostic testing and genetic screening programs. Key trends expected over this period include a rising adoption of gene therapy for otc deficiency, an increasing focus on personalized and targeted treatment approaches, growing awareness about early diagnosis through genetic testing, rising demand for enzyme replacement and protein engineering therapies, and an increasing clinical emphasis on ammonia level monitoring and management.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp
What Key Drivers Are Fueling The Growth Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
The ornithine transcarbamylase deficiency market is projected to experience growth driven by the rising demand for gene therapies. Gene therapy involves a medical approach that alters or manipulates a person’s genetic material to either treat or prevent diseases. This heightened demand for gene therapies is a result of the increasing prevalence of genetic disorders, as these conditions frequently have limited therapeutic options, and gene therapy presents a promising strategy to address the fundamental cause rather than merely managing symptoms. Ornithine transcarbamylase deficiency exemplifies the potential of gene therapies by correcting the genetic mutation that interferes with the urea cycle, thereby enabling a targeted treatment to restore metabolic function and prevent the accumulation of toxic ammonia. For example, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, stated that in Q4 2023, the quantity of gene therapies in Phase III grew by 10% from the preceding quarter, representing the first increase since Q3 2022. Hence, the escalating demand for gene therapies is propelling the growth of the ornithine transcarbamylase deficiency market.
What Segment Categories Shape The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segment Landscape?
The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –
1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC
2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types
3) By Diagnosis: Genetic Testing, Ammonia Level Testing
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation
2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination
3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach
4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy
What Trends Are Influencing The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
Leading firms within the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on creating novel treatments, including mRNA therapeutics, to improve the effectiveness of care and target the fundamental genetic origin of OTC deficiency. These mRNA-based therapies represent a category of medical interventions utilizing messenger RNA (mRNA) to direct cells in synthesizing particular proteins for therapeutic aims. Such treatments harness the body’s inherent protein production mechanisms to combat various conditions, encompassing genetic disorders, infectious diseases, and different forms of cancer. A notable example occurred in June 2023, when Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, their experimental mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency. This designation aims to expedite the drug’s development and regulatory review pathway, potentially providing advantages like increased engagement with the FDA and expedited review. The design of ARCT-810 intends to allow individuals suffering from OTC deficiency, which is a urea cycle disorder, to generate a functional OTC enzyme within their liver cells, thereby targeting the root cause of the ailment and potentially enhancing their overall quality of life.
Who Are The Companies Operating Across The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Value Chain?
Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.
Get The Full Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report:
Which Region Represents The Largest Share Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company
Oryzanol Market Report 2026
https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report
Orthobiologics Market Report
https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report
Auditing Services Market Report
https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model